Solid Forms of Ceftolozane

Patent metadata

Field	Value
Publication number	US-2016228448-A1
Application number	US-201415023935-A
Country	US
Kind code	A1
Filing date	Sep 25, 2014
Priority date	Sep 27, 2013
Publication date	Aug 11, 2016
Grant date	—

Abstract

Ceftolozane Sulfate is a cephalosporin antibacterial agent. Novel, stable, solid forms of the pharmaceutically acceptable sulfate salt of ceftolozane have been isolated via lyophilization. Characterization and identification of these solid forms by XRPD and Raman IR, as well as methods for their preparation and use in pharmaceutical compositions, are described.

First claim

1 . A solid form of ceftolozane sulfate that produces an X-ray powder diffraction (XRPD) pattern having diffractions at angles (2 theta±0.2) of 12.4, 16.4, 22.6, 25.1, and 28.0.

2 . The solid form of ceftolozane sulfate of claim 1 that produces Raman shift peaks (±5 cm −1 ) at about 171 cm −1 , 743 cm −1 , 819 cm −1 , 1055 cm −1 , 2894 cm −1 and 2976 cm −1 .

3 . A solid form of ceftolozane sulfate that produces:
a. an X-ray powder diffraction (XRPD) pattern having diffractions at angles (2 theta±0.2) of 24.2 and 37.8 and b. Raman shift peaks (±5 cm −1 ) at about 597 cm −1 , 716 cm −1 and 1329 cm −1 .

4 . The solid form of ceftolozane sulfate of claim 3 that produces an X-ray powder diffraction (XRPD) pattern having additional diffractions at angles (2 theta±0.2) of 12.4, 16.4, 22.6, 25.1, and 28.0.

5 . (canceled)

6 . (canceled)

7 . A pharmaceutical composition comprising a lyophilized ceftolozane composition obtained by a process comprising the steps of:
a. combining the ceftolozane sulfate of claim 1 , in a solid form designated herein as ceftolozane sulfate Form 1 with water to form an aqueous solution; and b. lyophilizing the aqueous solution to form the lyophilized ceftolozane composition comprising ceftolozane sulfate.

8 . The pharmaceutical composition of claim 7 , wherein the lyophilization cycle is characterized by one or more of the following characteristics:
a. not more than 150 mg ceftolozane free base/g bulk solution concentration, b. no more than 3 cm fill depth, c. freezing to at least −40° C. during the lyophilization cycle, d. drying to no more than 40° C., and e. single- or multi-step drying and setting chamber pressure during the start of primary drying at not more than 400 μbar.

9 . The pharmaceutical composition of claim 8 , further comprising tazobactam.

10 . The pharmaceutical composition of claim 9 , obtained by a process further comprising combining the lyophilized ceftolozane composition with tazobactam in a fixed dose combination providing about 500 mg of tazobactam active per 1,000 mg of ceftolozane active in the pharmaceutical composition.

11 . (canceled)

12 . A pharmaceutical composition comprising ceftolozane sulfate of claim 1 , obtained by a process comprising the steps of:
a. forming a solution comprising water, 72-100 g/L ceftolozane active and 1.5-2.95 molar equivalents of sulfuric acid to ceftolozane; b. combining the solution from step (a) with 20-40 volumes of isopropyl alcohol added to the solution over 0.5-8 hours to obtain solid ceftolozane sulfate; and c. isolating the solid ceftolozane sulfate composition from the solution.

13 . (canceled)

14 . (canceled)

15 . (canceled)

16 . The ceftolozane sulfate composition of claim 12 , wherein the solution from step (a) is combined with isopropyl alcohol added to the solution over 6-7 hours to obtain solid ceftolozane sulfate.

17 . (canceled)

18 . The ceftolozane sulfate composition of claim 12 , obtained by a process further comprising the steps of:
a. combining the isolates solid ceftolozane sulfate with water form a second aqueous solution; and b. lyophilizing the second aqueous solution to form a lyophilized ceftolozane pharmaceutical composition comprising ceftolozane sulfate.

19 . (canceled)

20 . The ceftolozane sulfate composition of claim 18 , obtained by a process further comprising the step of combining the lyophilized ceftolozane pharmaceutical composition with tazobactam.

21 . (canceled)

22 . (canceled)

23 . A solid form of ceftolozane sulfate that produces an X-ray powder diffraction (XRPD) pattern having diffractions at angles (2 theta±0.2) of 4.4, 8.8, 11.0, 14.9, and 17.7.

24 . The solid form of ceftolozane sulfate of claim 23 that produces Raman shift peaks (±5 cm −1 ) at about 151 cm −1 , 684 cm −1 , and 802 cm −1 .

25 . The solid form of ceftolozane sulfate of claim 23 characterized by a differential scanning calorimetry (DSC) endotherm having a minima at about 105 degrees C.

26 .- 48 . (canceled)

49 . A pharmaceutical composition comprising a lyophilized ceftolozane composition obtained by a process comprising the steps of:
a. combining the ceftolozane sulfate of claim 23 in a solid form that produces an X-ray powder diffraction (XRPD) pattern having diffractions at angles (2 theta±0.2) of 4.4, 8.8, 11.0, 14.9, and 17.7 with water to form an aqueous solution; and b. lyophilizing the aqueous solution to form the lyophilized ceftolozane composition comprising ceftolozane sulfate,
wherein the composition does not comprise a ceftolozane material having the combination of XRPD peaks described in Table 1a:

TABLE 1a

X-ray powder diffraction analysis (by Rigaku

X-ray Diffraction system MultiFlex)

2θ

8.0

12.7

13.8

16.1

18.9

20.4

21.5

22.4

23.3

24.0

25.5

26.7

27.9

28.5

31.3

X-ray: Cu/40 kV/30 mA

50 . The pharmaceutical composition of claim 49 , wherein the aqueous solution in step b) further comprises tazobactam.

51 . Use of a ceftolozane in an injectable preparation for treatment of an infection, the injectable preparation comprising a lyophilized ceftolozane composition obtained by a process comprising the steps of:
a. combining the ceftolozane sulfate of claim 23 , in a solid form that produces an X-ray powder diffraction (XRPD) pattern having diffractions at angles (2 theta±0.2) of 4.4, 8.8, 11.0, 14.9, and 17.7 with water to form an aqueous solution; and b. lyophilizing the aqueous solution to form the lyophilized ceftolozane composition comprising ceftolozane sulfate.

Assignees

• Merck Sharp & Dohme

Inventors

• Hwang You Seok
• Damour Nicole Miller
• Duong Lisa
• Jurkauskas Valdas
• Moshos Kristos Adrian
• Mudur Sanjay
• Ovat Asli
• Terracciano Joseph
• Woertink Jason

Classifications

• C07D501/57

  with a further substituent in position 7, e.g. cephamycines · CPC title

• A61K47/10

  Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers · CPC title

• A61K31/546 Primary

  containing further heterocyclic rings, e.g. cephalothin · CPC title

• A61K31/431

  containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin · CPC title

• C07D501/46

  with the 7-amino radical acylated by carboxylic acids containing hetero rings · CPC title